Form D · Pharmaceuticals

LEAP THERAPEUTICS, INC.

Cambridge, MA · CIK 0001509745

Offering snapshot reported Mar 13, 2023 · SEC filing

Reported sold
$77.2M
Offering amount: $77.2M
Investors reported
121
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jan 17, 2023
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Mar 13, 2023Initial$77,219,193No comparison121SEC filing
Nov 29, 2017Initial$18,000,001No comparison14SEC filing
Jan 7, 2011Initial$9,930,400No comparison4SEC filing

Offering details

Securities
Equity, Option to acquire, Other
Exemptions
06b
Duration over one year
No
Business combination
Yes
Sales commissions
$0
Finders' fees
$0
Form D file number
021-475708
Common Stock; Series X Non-Voting Convertible Preferred Stock

Source: Form D, filed Mar 13, 2023. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
James Cavanaugh Director
Thomas Dietz Director
Christine Granfield Executive
Augustine Lawlor Executive
William Li Director
John Littlechild Director
Joseph Loscalzo Director
Patricia Martin Director
Nissim Mashiach Director
Christopher K. Mirabelli Director
Mark O'mahony Executive
Douglas E. Onsi Director, Executive
Christian Richard Director
Richard Schilsky Director
Cynthia Sirard Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
47 Thorndike Street Suite B1 1
Cambridge, MA, 02142